BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

FDA’s approval of Celgene’s multiple sclerosis drug Zeposia ozanimod represents the first domino to fall among three that could lead to a big payout for Celgene’s former shareholders, who would be owed a contingent value...
BC Extra | Dec 11, 2019
Financial News

Omega seeking broad swath of deal types for $438M sixth fund

For its sixth and largest investment vehicle, Omega Funds intends to deploy a variety of investment tools in deals spanning early and late stage companies, with an emphasis on proven management teams. As Omega invests...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Week In Review | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Feb. 7 . Gossamer was up $1.94 (12%) to $17.94 on its first day of trading Feb. 8. Launched officially just 13 months...
BC Extra | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation,...
BC Week In Review | Jan 25, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

In a bid to keep its IPO from getting bogged down by the U.S. government shutdown, Gossamer Bio Inc. (San Diego, Calif.) plans to take advantage of a rule allowing a company to file to...
BC Extra | Jan 24, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

In a bid to keep its IPO from getting bogged down by the U.S. government shutdown, Gossamer Bio Inc. (San Diego, Calif.) plans to take advantage of a rule allowing a company to file to...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
BC Extra | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
Items per page:
1 - 10 of 154
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

FDA’s approval of Celgene’s multiple sclerosis drug Zeposia ozanimod represents the first domino to fall among three that could lead to a big payout for Celgene’s former shareholders, who would be owed a contingent value...
BC Extra | Dec 11, 2019
Financial News

Omega seeking broad swath of deal types for $438M sixth fund

For its sixth and largest investment vehicle, Omega Funds intends to deploy a variety of investment tools in deals spanning early and late stage companies, with an emphasis on proven management teams. As Omega invests...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Week In Review | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Feb. 7 . Gossamer was up $1.94 (12%) to $17.94 on its first day of trading Feb. 8. Launched officially just 13 months...
BC Extra | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation,...
BC Week In Review | Jan 25, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

In a bid to keep its IPO from getting bogged down by the U.S. government shutdown, Gossamer Bio Inc. (San Diego, Calif.) plans to take advantage of a rule allowing a company to file to...
BC Extra | Jan 24, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

In a bid to keep its IPO from getting bogged down by the U.S. government shutdown, Gossamer Bio Inc. (San Diego, Calif.) plans to take advantage of a rule allowing a company to file to...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
BC Extra | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
Items per page:
1 - 10 of 154